This bill amends the FAST Act to adjust funding limits for federal permitting improvement programs. It directly affects agencies and projects that rely on these specific funding allocations under the existing law. The key provision replaces a $200 million funding cap with a $50 million cap in two sections of the FAST Act. These changes take effect on January 1, 2027, or upon enactment, whichever occurs later.
HR 6213, the Heat Workforce Standards Act of 2025, prohibits the U.S. Department of Labor from finalizing, implementing, or enforcing OSHA's proposed "Heat Injury and Illness Prevention" standard (published August 30, 2024). This bill directly blocks the specific regulatory proposal targeting heat safety in both outdoor and indoor work settings. It does not create new requirements or affect workers; it solely prevents the implementation of the existing OSHA proposal. The bill is procedural, focusing on halting a regulatory action rather than establishing new policy.
HR 4986, the Parents Opt-in Protection Act, amends federal law to require written permission before schools administer certain student surveys or evaluations. It directly affects students (especially minors) and their parents, requiring schools to obtain prior written consent from the student (if an adult or emancipated minor) or the parent (for minors) for each specific survey. The bill clarifies that schools cannot force participation without this written consent for surveys related to sensitive topics like health or behavior. This change updates existing consent rules from verbal permission to a written requirement for targeted school assessments.
The AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.
This bill establishes the INCLUDE Project at the National Institutes of Health (NIH) to advance research on Down syndrome and related health conditions. It requires NIH to fund high-risk studies on trisomy 21, support inclusive clinical trials for people with Down syndrome across all ages, and investigate co-occurring conditions like Alzheimer’s disease and autoimmunity. The law mandates NIH coordination across its institutes, consultation with patient advocates, and biennial reports to Congress detailing funded research and its real-world applications. The project directly affects individuals with Down syndrome, their families, and medical researchers, aiming to improve diagnosis, treatment, and quality of life through targeted scientific efforts.
HR 2821, the FDA Modernization Act 3.0, requires the FDA to update regulatory language within one year of enactment. It directs the agency to replace all references to "animal tests" with "nonclinical tests" in 22 specific sections of the Code of Federal Regulations related to drug development and approval processes. The bill also adds a definition for "nonclinical test" into relevant FDA regulations to align with prior legislative changes. This update applies directly to pharmaceutical manufacturers and FDA reviewers who follow these regulatory guidelines during drug development. The changes aim to modernize terminology without altering current testing requirements.
HR 2004, titled "Tyler’s Law," requires the Secretary of Health and Human Services to study how often hospital emergency departments test for fentanyl during overdose cases (beyond standard drug tests), including associated costs, patient benefits/risks, and impacts on privacy and patient-physician relationships. The study must be completed within one year of the bill's enactment. Based on the study results, the Secretary must issue guidance within six months on whether emergency departments should routinely test for fentanyl, how to inform clinicians about test contents, and how such testing may affect future overdose risks and health outcomes. This bill directly affects hospital emergency departments and patients experiencing overdoses by shaping future testing protocols.
HR 1266, the Combating Illicit Xylazine Act, adds xylazine - a veterinary sedative increasingly found in illicit drug mixtures - to Schedule III of the Controlled Substances Act, regulating its use and trafficking. It directly affects veterinarians, animal owners, and manufacturers by allowing xylazine to be legally dispensed for animal use under specific veterinary prescriptions, while prohibiting non-veterinary human use. The bill includes transition periods (60 days for practitioners, 1 year for labeling) to ease compliance for manufacturers and practitioners, and requires the DEA and FDA to expedite necessary applications. It also mandates two congressional reports on xylazine's illicit use and trafficking patterns, and directs the Sentencing Commission to review penalties for offenses involving xylazine.
The National Coordination on Resilience for Security Act of 2026 creates a new Chief Resilience Officer within the National Security Council to lead federal efforts in preparing for natural hazards and enhancing national security. This official will establish interagency working groups and a Partners Council on Resilience that includes representatives from state, local, tribal, and private sector entities to coordinate strategies and identify funding gaps. The bill requires the development of a National Resilience Strategy that outlines how federal agencies will collaborate with non-federal partners to improve infrastructure, reduce waste, and support vulnerable communities. Additionally, the act mandates the creation of a public clearinghouse to share resilience data and technical assistance, with all provisions set to expire after ten years or following a third independent assessment.
The Weaponization Offender Claims Ban Act of 2026 restricts the ability of certain individuals to file civil lawsuits under the Federal Tort Claims Act. Specifically, it bars private citizens from bringing these claims if they have been convicted of crimes such as assaulting federal law enforcement officers, interfering with federal elections, obstructing government processes, or committing felonies involving theft or misuse of federal funds. This provision applies regardless of whether the convicted person has received a pardon or had their sentence commuted. The bill directly affects individuals with these specific criminal convictions who might otherwise seek legal redress against the federal government.
The Stop PRC Economic Espionage Act of 2026 amends federal law to expand the definition of foreign instrumentality. This change allows the U.S. government to classify any entity domiciled in a covered nation, such as China, as a foreign instrumentality even if it is not directly owned or controlled by that government. The bill directly affects companies and organizations operating in these countries by subjecting them to stricter scrutiny under existing economic espionage laws. By broadening who can be considered a foreign agent, the legislation aims to close a loophole that previously required proof of direct government control to trigger certain legal restrictions.
This resolution honors the life and legacy of the late Senator Lindsey Olin Graham from South Carolina. It formally acknowledges his extensive career in the military, state government, and Congress, noting his service as a Senator and his roles as Chairman of the Judiciary and Budget committees. The Senate expresses its sorrow over his death and requests that this tribute be shared with the House of Representatives and Graham's family.
